DRMA · Dermata Therapeutics, Inc.

Dermata Therapeutics reported its first quarter 2026 financial results, reflecting the company's strategic pivot from pharmaceutical development to direct-to-consumer (DTC) skincare. The net loss narrowed to $1.8 million from $2.3 million in the same quarter last year, primarily driven by a significant reduction in research and development expenses, which fell to $0.4 million from $1.3 million. This decrease was attributed to lower clinical, CMC, and personnel costs as the company shifts focus. Conversely, selling, general and administrative expenses rose to $1.5 million from $1.1 million, due to increased marketing, audit, and legal fees associated with the new skincare brand, Tome. The company ended the quarter with $6.9 million in cash, down from $7.5 million at year-end 2025, after raising $2.0 million in net proceeds from its at-the-market financing facility. Management expects current cash to fund operations into the first quarter of 2027. Key upcoming milestones include the mid-2026 launch of the Tome Foundational Treatment, a once-weekly mask for skin renewal, and preparation for a second DTC product. The company also announced the hiring of Kyra Peckaitis as Vice President of Marketing to lead the Tome brand. The strategic pivot aims to accelerate commercialization and reduce regulatory burdens, though forward-looking statements caution about risks inherent in product development and commercialization.